208 related articles for article (PubMed ID: 28349250)
1. Curcumin improves treatment outcome of Takayasu arteritis patients by reducing TNF-α: a randomized placebo-controlled double-blind clinical trial.
Shao N; Jia H; Li Y; Li J
Immunol Res; 2017 Aug; 65(4):969-974. PubMed ID: 28349250
[TBL] [Abstract][Full Text] [Related]
2. Resveratrol improves treatment outcome and laboratory parameters in patients with Takayasu arteritis: A randomized double-blind and placebo-controlled trial.
Shi G; Hua M; Xu Q; Ren T
Immunobiology; 2017 Feb; 222(2):164-168. PubMed ID: 27771172
[TBL] [Abstract][Full Text] [Related]
3. Effects of resistance exercise on treatment outcome and laboratory parameters of Takayasu arteritis with magnetic resonance imaging diagnosis: A randomized parallel controlled clinical trial.
Li G; Liu F; Wang Y; Zhao M; Song Y; Zhang L
Clin Cardiol; 2020 Nov; 43(11):1273-1278. PubMed ID: 32761844
[TBL] [Abstract][Full Text] [Related]
4. Profiles of serum cytokine levels in Takayasu arteritis patients: Potential utility as biomarkers for monitoring disease activity.
Tamura N; Maejima Y; Tezuka D; Takamura C; Yoshikawa S; Ashikaga T; Hirao K; Isobe M
J Cardiol; 2017 Sep; 70(3):278-285. PubMed ID: 27989502
[TBL] [Abstract][Full Text] [Related]
5. A Novel Highly Bioavailable Curcumin Formulation Improves Symptoms and Diagnostic Indicators in Rheumatoid Arthritis Patients: A Randomized, Double-Blind, Placebo-Controlled, Two-Dose, Three-Arm, and Parallel-Group Study.
Amalraj A; Varma K; Jacob J; Divya C; Kunnumakkara AB; Stohs SJ; Gopi S
J Med Food; 2017 Oct; 20(10):1022-1030. PubMed ID: 28850308
[TBL] [Abstract][Full Text] [Related]
6. Short-term effect of leflunomide in patients with Takayasu arteritis: an observational study.
de Souza AW; da Silva MD; Machado LS; Oliveira AC; Pinheiro FA; Sato EI
Scand J Rheumatol; 2012 May; 41(3):227-30. PubMed ID: 22400913
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of Biological-Targeted Treatments in Takayasu Arteritis: Multicenter, Retrospective Study of 49 Patients.
Mekinian A; Comarmond C; Resche-Rigon M; Mirault T; Kahn JE; Lambert M; Sibilia J; Néel A; Cohen P; Hie M; Berthier S; Marie I; Lavigne C; Anne Vandenhende M; Muller G; Amoura Z; Devilliers H; Abad S; Hamidou M; Guillevin L; Dhote R; Godeau B; Messas E; Cacoub P; Fain O; Saadoun D;
Circulation; 2015 Nov; 132(18):1693-700. PubMed ID: 26354797
[TBL] [Abstract][Full Text] [Related]
8. Anti TNF-α in refractory Takayasu's arteritis: cases series and review of the literature.
Comarmond C; Plaisier E; Dahan K; Mirault T; Emmerich J; Amoura Z; Cacoub P; Saadoun D
Autoimmun Rev; 2012 Jul; 11(9):678-84. PubMed ID: 22155781
[TBL] [Abstract][Full Text] [Related]
9. Serial analysis of clinical and imaging indices reveals prolonged efficacy of TNF-α and IL-6 receptor targeted therapies in refractory Takayasu arteritis.
Youngstein T; Peters JE; Hamdulay SS; Mewar D; Price-Forbes A; Lloyd M; Jeffery R; Kinderlerer AR; Mason JC
Clin Exp Rheumatol; 2014; 32(3 Suppl 82):S11-8. PubMed ID: 24093733
[TBL] [Abstract][Full Text] [Related]
10. Serum levels of fetuin-A as a novel biomarker for disease activity in patients with Takayasu arteritis and granulomatous polyangiitis.
Karadeniz H; Güler AA; Koca G; Salman RB; Satış H; Ataş N; Babaoğlu H; Paşaoğlu H; Küçük H; Tufan A; Öztürk MA; Göker B; Haznedaroğlu Ş
Clin Rheumatol; 2022 Apr; 41(4):1169-1176. PubMed ID: 35013833
[TBL] [Abstract][Full Text] [Related]
11. The efficacy of mycophenolate mofetil in treating Takayasu arteritis: a systematic review and meta-analysis.
Dai D; Wang Y; Jin H; Mao Y; Sun H
Rheumatol Int; 2017 Jul; 37(7):1083-1088. PubMed ID: 28364217
[TBL] [Abstract][Full Text] [Related]
12. Adjuvant therapy with bioavailability-boosted curcuminoids suppresses systemic inflammation and improves quality of life in patients with solid tumors: a randomized double-blind placebo-controlled trial.
Panahi Y; Saadat A; Beiraghdar F; Sahebkar A
Phytother Res; 2014 Oct; 28(10):1461-7. PubMed ID: 24648302
[TBL] [Abstract][Full Text] [Related]
13. The effect of curcumin supplementation on clinical outcomes and inflammatory markers in patients with ulcerative colitis.
Sadeghi N; Mansoori A; Shayesteh A; Hashemi SJ
Phytother Res; 2020 May; 34(5):1123-1133. PubMed ID: 31802559
[TBL] [Abstract][Full Text] [Related]
14. Systemic pentraxin-3 levels reflect vascular enhancement and progression in Takayasu arteritis.
Tombetti E; Di Chio MC; Sartorelli S; Papa M; Salerno A; Bottazzi B; Bozzolo EP; Greco M; Rovere-Querini P; Baldissera E; Del Maschio A; Mantovani A; De Cobelli F; Sabbadini MG; Manfredi AA
Arthritis Res Ther; 2014 Nov; 16(6):479. PubMed ID: 25394473
[TBL] [Abstract][Full Text] [Related]
15. Pentraxin-3 as a marker of disease activity in Takayasu arteritis.
Dagna L; Salvo F; Tiraboschi M; Bozzolo EP; Franchini S; Doglioni C; Manfredi AA; Baldissera E; Sabbadini MG
Ann Intern Med; 2011 Oct; 155(7):425-33. PubMed ID: 21969341
[TBL] [Abstract][Full Text] [Related]
16. Tumor necrosis factor inhibitors in patients with Takayasu arteritis: experience from a referral center with long-term followup.
Schmidt J; Kermani TA; Bacani AK; Crowson CS; Matteson EL; Warrington KJ
Arthritis Care Res (Hoboken); 2012 Jul; 64(7):1079-83. PubMed ID: 22328491
[TBL] [Abstract][Full Text] [Related]
17. Development and initial validation of the Indian Takayasu Clinical Activity Score (ITAS2010).
Misra R; Danda D; Rajappa SM; Ghosh A; Gupta R; Mahendranath KM; Jeyaseelan L; Lawrence A; Bacon PA;
Rheumatology (Oxford); 2013 Oct; 52(10):1795-801. PubMed ID: 23594468
[TBL] [Abstract][Full Text] [Related]
18. Treatment of refractory Takayasu arteritis with tocilizumab: 7 Italian patients from a single referral center.
Tombetti E; Franchini S; Papa M; Sabbadini MG; Baldissera E
J Rheumatol; 2013 Dec; 40(12):2047-51. PubMed ID: 24187104
[TBL] [Abstract][Full Text] [Related]
19. TNF inhibitors appear to inhibit disease progression and improve outcome in Takayasu arteritis; an observational, population-based time trend study.
Gudbrandsson B; Molberg Ø; Palm Ø
Arthritis Res Ther; 2017 May; 19(1):99. PubMed ID: 28521841
[TBL] [Abstract][Full Text] [Related]
20. Cyclophosphamide for large vessel vasculitis: assessment of response by PET/CT.
Henes JC; Mueller M; Pfannenberg C; Kanz L; Kötter I
Clin Exp Rheumatol; 2011; 29(1 Suppl 64):S43-8. PubMed ID: 21385544
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
